Switch to:
Also traded in: Germany, Israel, Mexico, Switzerland, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.70
TEVJF's Cash to Debt is ranked lower than
70% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. TEVJF: 0.70 )
Ranked among companies with meaningful Cash to Debt only.
TEVJF' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.30 Max: 1.03
Current: 0.7
0.08
1.03
Equity to Asset 0.55
TEVJF's Equity to Asset is ranked lower than
60% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TEVJF: 0.55 )
Ranked among companies with meaningful Equity to Asset only.
TEVJF' s Equity to Asset Range Over the Past 10 Years
Min: 0.4  Med: 0.50 Max: 0.59
Current: 0.55
0.4
0.59
Interest Coverage 10.11
TEVJF's Interest Coverage is ranked lower than
66% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. TEVJF: 10.11 )
Ranked among companies with meaningful Interest Coverage only.
TEVJF' s Interest Coverage Range Over the Past 10 Years
Min: 3.6  Med: 12.64 Max: N/A
Current: 10.11
F-Score: 6
Z-Score: 2.22
WACC vs ROIC
5.14%
2.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.88
TEVJF's Operating margin (%) is ranked higher than
54% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. TEVJF: 9.88 )
Ranked among companies with meaningful Operating margin (%) only.
TEVJF' s Operating margin (%) Range Over the Past 10 Years
Min: 8.12  Med: 17.02 Max: 25.46
Current: 9.88
8.12
25.46
Net-margin (%) 8.08
TEVJF's Net-margin (%) is ranked higher than
56% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. TEVJF: 8.08 )
Ranked among companies with meaningful Net-margin (%) only.
TEVJF' s Net-margin (%) Range Over the Past 10 Years
Min: 5.73  Med: 12.03 Max: 20.75
Current: 8.08
5.73
20.75
ROE (%) 6.47
TEVJF's ROE (%) is ranked lower than
52% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. TEVJF: 6.47 )
Ranked among companies with meaningful ROE (%) only.
TEVJF' s ROE (%) Range Over the Past 10 Years
Min: 4.23  Med: 10.00 Max: 16.18
Current: 6.47
4.23
16.18
ROA (%) 3.22
TEVJF's ROA (%) is ranked lower than
53% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. TEVJF: 3.22 )
Ranked among companies with meaningful ROA (%) only.
TEVJF' s ROA (%) Range Over the Past 10 Years
Min: 2.26  Med: 4.98 Max: 9.34
Current: 3.22
2.26
9.34
ROC (Joel Greenblatt) (%) 26.27
TEVJF's ROC (Joel Greenblatt) (%) is ranked higher than
67% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. TEVJF: 26.27 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TEVJF' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 16.82  Med: 33.66 Max: 49.49
Current: 26.27
16.82
49.49
Revenue Growth (3Y)(%) -0.80
TEVJF's Revenue Growth (3Y)(%) is ranked lower than
70% of the 594 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. TEVJF: -0.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TEVJF' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -0.8  Med: 15.60 Max: 23.4
Current: -0.8
-0.8
23.4
EBITDA Growth (3Y)(%) 6.60
TEVJF's EBITDA Growth (3Y)(%) is ranked lower than
53% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.70 vs. TEVJF: 6.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TEVJF' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.6  Med: 14.80 Max: 47.4
Current: 6.6
-9.6
47.4
EPS Growth (3Y)(%) -6.80
TEVJF's EPS Growth (3Y)(%) is ranked lower than
71% of the 501 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.20 vs. TEVJF: -6.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TEVJF' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -25.5  Med: 15.40 Max: 69.5
Current: -6.8
-25.5
69.5
» TEVJF's 10-Y Financials

Financials (Next Earnings Date: 2016-05-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TEVJF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Teva Pharmaceutical Industries Ltd

SymbolPriceYieldDescription
TEVVF889.312.147 % Conv.Cum.Pfd Shs Mandatory Conv. 15.12.2018

Ratios

vs
industry
vs
history
P/E(ttm) 29.58
TEVJF's P/E(ttm) is ranked lower than
54% of the 542 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.66 vs. TEVJF: 29.58 )
Ranked among companies with meaningful P/E(ttm) only.
TEVJF' s P/E(ttm) Range Over the Past 10 Years
Min: 10.53  Med: 20.42 Max: 1072.29
Current: 29.58
10.53
1072.29
PE(NRI) 29.58
TEVJF's PE(NRI) is ranked lower than
54% of the 539 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.62 vs. TEVJF: 29.58 )
Ranked among companies with meaningful PE(NRI) only.
TEVJF' s PE(NRI) Range Over the Past 10 Years
Min: 10.53  Med: 20.61 Max: 938.25
Current: 29.58
10.53
938.25
Price/Owner Earnings (ttm) 28.99
TEVJF's Price/Owner Earnings (ttm) is ranked higher than
58% of the 259 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.02 vs. TEVJF: 28.99 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TEVJF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 8.82  Med: 20.08 Max: 67.1
Current: 28.99
8.82
67.1
P/B 1.85
TEVJF's P/B is ranked higher than
67% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. TEVJF: 1.85 )
Ranked among companies with meaningful P/B only.
TEVJF' s P/B Range Over the Past 10 Years
Min: 1.36  Med: 2.27 Max: 4.81
Current: 1.85
1.36
4.81
P/S 2.37
TEVJF's P/S is ranked higher than
55% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. TEVJF: 2.37 )
Ranked among companies with meaningful P/S only.
TEVJF' s P/S Range Over the Past 10 Years
Min: 1.58  Med: 3.01 Max: 5.83
Current: 2.37
1.58
5.83
POCF 8.36
TEVJF's POCF is ranked higher than
80% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.79 vs. TEVJF: 8.36 )
Ranked among companies with meaningful POCF only.
TEVJF' s POCF Range Over the Past 10 Years
Min: 6.58  Med: 11.92 Max: 23.43
Current: 8.36
6.58
23.43
EV-to-EBIT 28.50
TEVJF's EV-to-EBIT is ranked lower than
67% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. TEVJF: 28.50 )
Ranked among companies with meaningful EV-to-EBIT only.
TEVJF' s EV-to-EBIT Range Over the Past 10 Years
Min: 11.4  Med: 20.55 Max: 991
Current: 28.5
11.4
991
EV-to-EBITDA 21.35
TEVJF's EV-to-EBITDA is ranked lower than
61% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. TEVJF: 21.35 )
Ranked among companies with meaningful EV-to-EBITDA only.
TEVJF' s EV-to-EBITDA Range Over the Past 10 Years
Min: 9  Med: 17.15 Max: 290.6
Current: 21.35
9
290.6
PEG 11.96
TEVJF's PEG is ranked lower than
90% of the 279 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.91 vs. TEVJF: 11.96 )
Ranked among companies with meaningful PEG only.
TEVJF' s PEG Range Over the Past 10 Years
Min: 0.32  Med: 1.10 Max: 119.22
Current: 11.96
0.32
119.22
Shiller P/E 23.52
TEVJF's Shiller P/E is ranked higher than
77% of the 145 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 45.10 vs. TEVJF: 23.52 )
Ranked among companies with meaningful Shiller P/E only.
TEVJF' s Shiller P/E Range Over the Past 10 Years
Min: 18.72  Med: 31.85 Max: 101.16
Current: 23.52
18.72
101.16
Current Ratio 1.41
TEVJF's Current Ratio is ranked lower than
77% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. TEVJF: 1.41 )
Ranked among companies with meaningful Current Ratio only.
TEVJF' s Current Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.59 Max: 2.95
Current: 1.41
1.06
2.95
Quick Ratio 1.11
TEVJF's Quick Ratio is ranked lower than
71% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. TEVJF: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
TEVJF' s Quick Ratio Range Over the Past 10 Years
Min: 0.69  Med: 1.08 Max: 2.18
Current: 1.11
0.69
2.18
Days Inventory 183.28
TEVJF's Days Inventory is ranked lower than
78% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.30 vs. TEVJF: 183.28 )
Ranked among companies with meaningful Days Inventory only.
TEVJF' s Days Inventory Range Over the Past 10 Years
Min: 131.65  Med: 186.40 Max: 208.14
Current: 183.28
131.65
208.14
Days Sales Outstanding 99.37
TEVJF's Days Sales Outstanding is ranked lower than
66% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.16 vs. TEVJF: 99.37 )
Ranked among companies with meaningful Days Sales Outstanding only.
TEVJF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 95.91  Med: 123.91 Max: 153.21
Current: 99.37
95.91
153.21

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.07
TEVJF's Price/Projected FCF is ranked higher than
83% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. TEVJF: 1.07 )
Ranked among companies with meaningful Price/Projected FCF only.
TEVJF' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.66  Med: 1.51 Max: 7.38
Current: 1.07
0.66
7.38
Price/DCF (Earnings Based) 2.30
TEVJF's Price/DCF (Earnings Based) is ranked lower than
77% of the 71 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. TEVJF: 2.30 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.79
TEVJF's Price/Median PS Value is ranked higher than
80% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. TEVJF: 0.79 )
Ranked among companies with meaningful Price/Median PS Value only.
TEVJF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.53  Med: 1.03 Max: 1.85
Current: 0.79
0.53
1.85
Earnings Yield (Greenblatt) (%) 3.54
TEVJF's Earnings Yield (Greenblatt) (%) is ranked higher than
53% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. TEVJF: 3.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TEVJF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 4.90 Max: 8.8
Current: 3.54
0.1
8.8
Forward Rate of Return (Yacktman) (%) -9.29
TEVJF's Forward Rate of Return (Yacktman) (%) is ranked lower than
78% of the 316 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.27 vs. TEVJF: -9.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TEVJF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -10  Med: 22.05 Max: 43.7
Current: -9.29
-10
43.7

More Statistics

Revenue(Mil) $19652
EPS $ 1.82
Beta-0.50
Short Percentage of Float0.00%
52-Week Range $57.25 - 69.24
Shares Outstanding(Mil)907.66

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 23,732 25,160 26,046
EPS($) 5.60 6.10 6.59
EPS without NRI($) 5.60 6.10 6.59

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:NYSE:AGN, TSE:4502, BOM:524715, NYSE:ZTS, NAS:MYL » details
Traded in other countries:TEV.Germany, TEVA.Israel, TEVAN.Mexico, TEVA.Switzerland, TEVA.USA,
Teva Pharmaceutical Industries Ltd was incorporated in Israel on February 13, 1944. The Company manufactures generic pharmaceutical products. It operates in business in two segments such as generic products, which includes chemical and therapeutic equivalents of originator pharmaceuticals in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants, as well as API business; and specialty products, which includes several core franchises, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines, as well as other areas such as oncology and women's health. In addition to these two segments, the Company has other activities, primarily PGT Healthcare, OTC joint venture with P&G, distribution services primarily in Israel and Hungary, and sales of medical devices. The Company, along with its subsidiaries operates in approximately 60 countries. It develops, manufactures and sell generic pharmaceutical products in a variety of dosage forms, including tablets, capsules, ointments, creams, liquids, injectables and inhalants. Specialty medicines business, which is focused on delivering solutions to patients and providers via medicines, devices and services in all key regions and markets around the world, includes several core therapeutic areas, medicines for CNS disorders (with a strong emphasis on MS, neurodegenerative disorders, and pain) and respiratory medicines. Some of its products are Copaxone, Azilect & Provigil, among others. The Company markets approximately 375 generic products in more than 1,100 dosage strengths and packaging sizes, including oral, injectables and inhaled products. The Company is subject to extensive regulation by the United States federal government, principally by the FDA and the Drug Enforcement Administration ("DEA").
» More Articles for TEVJF

Headlines

Articles On GuruFocus.com
John Keeley Comments on Teva Pharmaceuticals Apr 26 2016 
Pfizer-Allergen Merger Deal End Hurts Some Funds But Helps Many Apr 08 2016 
Time To Buy Allergan Apr 06 2016 
Health Care Investor Larry Robbins Buys HCA Holdings, Cigna Mar 31 2016 
Fight Market Malaise with These Four Sector Strategies Mar 30 2016 
Bernard Horn Comments on Teva Pharmaceutical Mar 21 2016 
Polaris Global Value Fund Annual Letter 2015 Mar 21 2016 
John Paulson Raises Stake in Valeant, Teva Pharmaceutical Mar 18 2016 
Andreas Halvorsen Raises Stake in Teva Pharmaceutical Mar 09 2016 
Julian Robertson Buys 8 New Stakes in 4th Quarter Mar 09 2016 

More From Other Websites
What's behind spike in Teva put volume May 03 2016
Put buying hits Teva ahead of earnings May 03 2016
Major Pharma Short Interest Remains Mixed, With 1 Massive Drop Apr 27 2016
Teva migraine awareness campaign features Hollywood actress Apr 26 2016
Goldman Sach's 5 Large-Cap Pharma Stock Favorites Ahead of Earnings Apr 25 2016
A Look at Zach Schreiber’s Top Picks Ahead of His Ira Sohn Presentation Apr 21 2016
Why Has Teva Pharmaceutical Targeted Orphan Diseases? Apr 14 2016
CIO Voices: Allergan's Sean Lennon Says Never Presume Job Security in a Merger Apr 13 2016
Teva Pharmaceutical: Label Expansion Plans in 2016 Apr 13 2016
Short Sellers Become More Selective in Major Pharma Apr 12 2016
[$$] Four Buys After the Specialty-Pharma Selloff Apr 08 2016
Israel Remains A Developed Market Opportunity Apr 08 2016
These 5 Stocks Look Toxic in April Apr 08 2016
This 'Boring' Drugmaker Could Gain 76% as Biotech Sector Bounces Back Apr 07 2016
Allergan, Pfizer Strike Off Down Separate Paths After Merger Killed Apr 06 2016
Teva’s Asthma Segment: What Could Its Boost Revenues in 2016? Apr 06 2016
Allergan: On My Own Apr 06 2016
Billionaire John Paulson’s 13F Picks Post 13% Drop in Q1 Apr 06 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK